ProMIS Neurosciences Inc.
PMNNasdaq
$15.19
↑ +14.2%Jul 17 close · end-of-day
Price
1Y↑ +35.0%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$99.2M
Enterprise Value
$35.3M
P/E
—
P/S
—
P/B
1.6
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$40.6M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-66.9%
ROIC
—
Debt / Equity
—
Net Cash
$63.8M
Return 1Y
+29.3%
Company profile
N/A
- CEO
- Gail M. Farfel
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 5
- Headquarters
- Ontario
- Website
- promisneurosciences.com
Management & directors
- Kaplan JohanneChief Development Officer
- Cashman NeilChief Scientific Officer
- Warma Neil KChief Executive Officer
Roles derived from SEC Form 4 filings.
Earnings
PMN Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$1.26↓ -76.1%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$8.3M | -$23.4M | -$14.3M | -$16.8M | -$40.2M |
| Net income | -$9.8M | -$18.1M | -$13.2M | $2.8M | -$39.7M |
| Diluted EPS | -$1.69 | -$2.41 | -$1.07 | $2.63 | -$22.61 |
| Operating cash flow | -$9.3M | -$17.0M | -$10.8M | -$27.2M | -$28.1M |
| Free cash flow | -$9.3M | -$17.0M | — | — | — |
| Gross margin | — | — | — | — | — |
| Operating margin | — | — | — | — | — |
| Net margin | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$2.7M | -$4.4M | -$6.0M | -$7.5M | -$10.2M | -$11.8M | -$10.8M | -$8.6M |
| Net income | -$2.6M | $9.3M | -$238,207.00 | -$7.3M | -$10.1M | -$11.6M | -$10.7M | -$8.2M |
| Diluted EPS | -$0.13 | $0.31 | $2.64 | -$5.27 | -$0.29 | -$0.24 | -$16.81 | -$1.26 |
| Operating cash flow | -$1.5M | -$6.7M | -$8.7M | -$4.9M | -$3.9M | -$10.1M | -$9.3M | -$12.4M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jun 12, 2026
May 28, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-04-22 | Kirwin Patrick D. | Buy | 4,000 | $11.33 | $45,320.00 | filing |
| 2026-03-05 | Williams Eugene | Buy | 2,000 | $24.40 | $48,800.00 | filing |
| 2026-03-04 | Williams Eugene | Buy | 2,000 | $24.00 | $48,000.00 | filing |
| 2026-03-03 | Williams Eugene | Buy | 1,000 | $21.89 | $21,890.00 | filing |
| 2026-03-02 | Williams Eugene | Buy | 1,000 | $22.53 | $22,530.00 | filing |
| 2026-02-19 | Kaplan Johanne· Chief Development Officer | Buy | 1,629 | $15.35 | $25,005.15 | filing |
| 2026-02-03 | ABG Management Ltd. | Buy | 700,741 | $12.13 | $8.5M | filing |
| 2026-02-03 | Milbury Max A. | Award | 6,595 | $12.13 | $79,997.35 | filing |
| 2026-02-03 | Warma Neil K· Chief Executive Officer | Award | 6,183 | $12.13 | $74,999.79 | filing |
| 2026-02-03 | Cashman Neil· Chief Scientific Officer | Award | 4,122 | $12.13 | $49,999.86 | filing |
| 2026-02-03 | Kirwin Patrick D. | Award | 3,050 | $12.13 | $36,996.50 | filing |
| 2026-02-03 | Kaplan Johanne· Chief Development Officer | Award | 2,060 | $12.13 | $24,987.80 | filing |
| 2025-10-03 | Milbury Max A. | Buy | 30,392 | $0.49 | $14,928.55 | filing |
| 2025-07-25 | Jeremy M. Sclar 2012 Irrevocable Family Trust | X | 697,674 | — | — | filing |
| 2025-07-25 | Jeremy M. Sclar 2012 Irrevocable Family Trust | X | 697,674 | — | — | filing |
| 2025-07-25 | Jeremy M. Sclar 2012 Irrevocable Family Trust | X | 697,674 | — | — | filing |
| 2025-07-25 | Sclar Jeremy M. | X | 697,674 | — | — | filing |
| 2025-07-25 | Sclar Jeremy M. | X | 697,674 | — | — | filing |
| 2025-07-25 | Sclar Jeremy M. | X | 697,674 | — | — | filing |
| 2025-07-25 | GORDON MICHAEL S | X | 119,800 | — | — | filing |
| 2025-07-25 | GORDON MICHAEL S | X | 119,800 | — | — | filing |
| 2025-07-25 | GORDON MICHAEL S | X | 119,800 | — | — | filing |
| 2025-07-25 | Title 19 Promis | X | 119,800 | — | — | filing |
| 2025-07-25 | Title 19 Promis | X | 119,800 | — | — | filing |
| 2025-07-25 | Title 19 Promis | X | 119,800 | — | — | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.